Home > Press > DNA nanoswitches rapidly detect Sars-Cov-2 and other emerging viruses: Programmable low-cost DNA-based platform for viral RNA detection
Abstract:Programmable...
Home > Press > Arrowhead Pharmaceuticals Initiates Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
Abstract:Arrowhead Pharmaceuticals...
Xcovery pitted its ALK inhibitor against Pfizer’s Xalkori—the first-ever FDA-approved drug in its class—and came out on top. The drug, ensartinib, shrank tumors...